Selenium‐Doped Carbon Quantum Dots Act as Broad‐Spectrum Antioxidants for Acute Kidney Injury Management

The manifestation of acute kidney injury (AKI) is associated with poor patient outcomes, with treatment options limited to hydration or renal replacement therapies. The onset of AKI is often associated with a surfeit of reactive oxygen species. Here, it is shown that selenium‐doped carbon quantum do...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Advanced science Ročník 7; číslo 12; s. 2000420 - n/a
Hlavní autoři: Rosenkrans, Zachary T., Sun, Tuanwei, Jiang, Dawei, Chen, Weiyu, Barnhart, Todd E., Zhang, Ziyi, Ferreira, Carolina A., Wang, Xudong, Engle, Jonathan W., Huang, Peng, Cai, Weibo
Médium: Journal Article
Jazyk:angličtina
Vydáno: Germany John Wiley & Sons, Inc 01.06.2020
John Wiley and Sons Inc
Wiley
Témata:
acute kidney injury
Antioxidants
Carbon
carbon quantum dots
cisplatin
FDA approval
Free radicals
Kidney diseases
Medical diagnosis
Microscopy
Nanomaterials
nanomedicine
Nanotechnology
Oxidative stress
positron emission tomography
Quantum dots
rhabdomyolysis
Selenium
Spectrum analysis
rhabdomyolysis
selenium
carbon quantum dots
nanomedicine
acute kidney injury
cisplatin
positron emission tomography
ISSN:2198-3844, 2198-3844
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The manifestation of acute kidney injury (AKI) is associated with poor patient outcomes, with treatment options limited to hydration or renal replacement therapies. The onset of AKI is often associated with a surfeit of reactive oxygen species. Here, it is shown that selenium‐doped carbon quantum dots (SeCQDs) have broad‐spectrum antioxidant properties and prominent renal accumulation in both healthy and AKI mice. Due to these properties, SeCQDs treat or prevent two clinically relevant cases of AKI induced in murine models by either rhabdomyolysis or cisplatin using only 1 or 50 µg per mouse, respectively. The attenuation of AKI in both models is confirmed by blood serum measurements, kidney tissue staining, and relevant biomarkers. The therapeutic efficacy of SeCQDs exceeds amifostine, a drug approved by the Food and Drug Administration that also acts by scavenging free radicals. The findings indicate that SeCQDs show great potential as a treatment option for AKI and possibly other ROS‐related diseases. The specific renal accumulation and excellent antioxidant properties of SeCQDs allows prevention and treatment of acute kidney injury.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2198-3844
2198-3844
DOI:10.1002/advs.202000420